Small clinical trials comparing them head-to-head at the different stages of prostate cancer can be needed. This may be done with asymptomatic Guys who've early Innovative-phase prostate cancer (e.g. PSA > sixty ng/ml); a downward change of PSA could be easily employed being a related biomarker endpoint in reasonably smaller and quick-phrase trials